Submitted by Penny Peck on Fri, 04/04/2025 - 15:23
Pretzel Therapeutics has announced the initiation of recruitment for a Phase 1 clinical study of PX578, the lead therapeutic in its bioenergetics restoration phase. The randomized, double-blind, placebo-controlled study is designed to evaluate the safety, tolerability and pharmacokinetics of single and multiple ascending doses of PX578 in healthy adult participants, with a potential clinical trial involving patients with mitochondrial DNA depletion syndrome (MDDS) being planned for 2026.
Pretzel Therapeutics was co-founded in 2022 by the MBU’s Mitochondrial Genetics Programme Leader, Michal Minczuk, along with other scientific co-founders: Claes Gustafsson and Maria Falkenberg from the University of Gothenburg as well as Nils-Göran Larsson from the Karolinska Institutet.